News & Partnering

Press releases

January 29, 2025

Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma

November 11, 2024

Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting

May 21, 2024

Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

November 20, 2023

Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma

In the News

December 20, 2024 | Game On Glio Podcast

Understand a powerful immuno-cancer therapy trial for brain tumors

November 25, 2024 | OncLive

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

Upcoming Events

None at this time, stay tuned!